Expensify (NASDAQ:EXFY) reported quarterly sales of $43.20 million which missed the analyst consensus estimate of $43.66 million by 1.05 percent.
Related Posts
CBD For Traumatic Brain Injuries? Oral Administration Reduces Levels Of Neuronal Death In Animal Model, New Study
HempMeds, a subsidiary of Medical Marijuana, Inc. (OTCPK:MJNA) took part in a collaboration on a study to demonstrate the effectiveness of hemp-based CBD in the treatment of Parkinson's Disease.
Sequential Brands Group Commences Voluntary Chapter 11 Proceedings
Sequential Brands Group, Inc. ("Sequential" or the "Company") (NASDAQ:SQBG) today announced that it, together with its wholly-owned subsidiaries, has commenced voluntary Chapter 11
EXCLUSIVE: Boxed To Expand E-Commerce In The Middle East, North Africa And Southeast Asia
A leading e-commerce company that sells bulk consumables and licenses its software to retailers announced a new partnership that increases its international expansion.